Assembly Bio reports positive Phase 1b topline results for ABI-4334 in chronic HBV; Gilead opt-in triggered

ASSEMBLY BIOSCIENCES, INC.

Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).
Favorable safety: no serious AEs or discontinuations; two grade 3 lab abnormalities resolved with continued dosing.
Half-life supports once-daily oral dosing; exposure at both doses achieved double-digit multiples over target EC50.
Data triggers Gilead's right to opt-in for exclusive license after review of option data package.
ABI-4334 shows potential to inhibit viral replication at 150 mg and cccDNA formation at higher doses.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.